BridgeBio Pharma Retained Earnings (Accumulated Deficit) 2018-2024 | BBIO
BridgeBio Pharma retained earnings (accumulated deficit) from 2018 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
BridgeBio Pharma Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$-2,561 |
| 2022 |
$-1,918 |
| 2021 |
$-1,437 |
| 2020 |
$-889 |
| 2019 |
$-440 |
| 2018 |
$-179 |
| 2017 |
$ |
BridgeBio Pharma Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-06-30 |
$-2,669 |
| 2024-03-31 |
$-2,596 |
| 2023-12-31 |
$-2,561 |
| 2023-09-30 |
$-2,392 |
| 2023-06-30 |
$-2,215 |
| 2023-03-31 |
$-2,057 |
| 2022-12-31 |
$-1,918 |
| 2022-09-30 |
$-1,781 |
| 2022-06-30 |
$-1,643 |
| 2022-03-31 |
$-1,633 |
| 2021-12-31 |
$-1,437 |
| 2021-09-30 |
$-1,290 |
| 2021-06-30 |
$-1,134 |
| 2021-03-31 |
$-1,038 |
| 2020-12-31 |
$-889 |
| 2020-09-30 |
$-769 |
| 2020-06-30 |
$-653 |
| 2020-03-31 |
$-532 |
| 2019-12-31 |
$-440 |
| 2019-09-30 |
$-367 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.629B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
